Profile data is unavailable for this security.
About the company
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
- Revenue in CAD (TTM)-16.37k
- Net income in CAD-2.67m
- Incorporated2006
- Employees--
- LocationSirona Biochem Corpc/o WeWork, 595 Burrard St.VANCOUVER V7X 1L4CanadaCAN
- Phone+1 (604) 641-4466
- Fax+1 (604) 608-5471
- Websitehttps://www.sironabiochem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telo Genomics Corp | 0.00 | -2.97m | 11.98m | 8.00 | -- | 19.03 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | 0.00 | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
Resverlogix Corp | 0.00 | -14.72m | 18.13m | 18.00 | -- | -- | -- | -- | -0.0565 | -0.0565 | 0.00 | -0.3845 | 0.00 | -- | -- | 0.00 | -138.80 | -- | -- | -- | -- | -- | -- | -- | 0.0459 | -0.8227 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
COSCIENS Biopharma Inc | 6.19m | -17.28m | 19.04m | 21.00 | -- | 0.4385 | -- | 3.07 | -12.83 | -12.83 | 3.66 | 11.74 | 0.0936 | 1.74 | 6.35 | -- | -26.11 | -26.24 | -30.53 | -30.34 | 39.42 | 83.68 | -278.95 | -300.31 | 3.05 | -- | 0.0604 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Sirona Biochem Corp | -16.37k | -2.67m | 19.50m | -- | -- | -- | -- | -- | -0.0105 | -0.0105 | -0.00006 | -0.0134 | -0.0171 | -- | 1.61 | -- | -278.90 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -5.73 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |